Cdc5L activators encompass a range of chemical agents that are developed to modulate the activity of the Cdc5L protein, a core component of the spliceosomal complex involved in pre-mRNA splicing-a critical step in gene expression where introns are removed and exons are joined to form a continuous coding sequence. Cdc5L is a member of the pre-mRNA splicing factor family and plays a pivotal role not only in splicing but also in the regulation of various aspects of cell cycle progression and DNA damage repair pathways.
Activators targeting Cdc5L may operate through direct interactions, binding to the protein and inducing allosteric changes that enhance its splicing activity or its interaction with other components of the spliceosome. By doing so, they can facilitate the assembly of the spliceosomal complex or increase the efficiency of the splicing process itself. Direct activators might mimic endogenous ligands or bind to unique regions of Cdc5L, thereby promoting its function in the splicing machinery. On the other hand, indirect activators of Cdc5L might work by influencing cellular signaling pathways that regulate the expression levels, localization, or post-translational modifications of the protein. These modifications can include phosphorylation, ubiquitination, or sumoylation, all of which can have profound effects on Cdc5L's activity and its interactions with other cellular components. Through these pathways, indirect activators can lead to enhanced Cdc5L-mediated splicing activity by promoting a favorable cellular context for its function. Research into Cdc5L activators is of significant interest in the field of molecular biology, particularly with respect to understanding the regulation of gene expression at the post-transcriptional level. Splicing is not only fundamental to the production of mature mRNA but also contributes to the diversity of the proteome through alternative splicing events that lead to the generation of different protein isoforms from a single gene.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid inhibits protein phosphatases PP1 and PP2A, which are involved in dephosphorylation events. This can enhance the phosphorylation state of Cdc5L, hence promoting its activity. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Calyculin A inhibits protein phosphatases PP1 and PP2A, thus maintaining proteins, like Cdc5L, in their phosphorylated states, and enhancing their activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels. This can trigger PKA activation, which in turn may phosphorylate and activate Cdc5L. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, resulting in increased cAMP levels. This can activate PKA and potentially lead to phosphorylation and activation of Cdc5L. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine binds to adrenergic receptors, leading to an increase in cAMP levels. The increased cAMP activates PKA, which can then phosphorylate and activate Cdc5L. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels, activating PKA. PKA can then phosphorylate and activate Cdc5L. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterases, leading to an increase in cAMP levels, which can activate PKA, potentially leading to the phosphorylation and activation of Cdc5L. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $107.00 $316.00 | 3 | |
Cilostazol inhibits PDE3 and increases cAMP levels, thus activating PKA. PKA can then phosphorylate and activate Cdc5L. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate and activate Cdc5L. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $240.00 | 9 | |
Bryostatin 1 activates PKC, which can phosphorylate and activate Cdc5L. |